On March 14, Yuan Shuai, deputy director of Pingshan District Science and Technology Innovation Bureau, led a team to Shenzhen Cell Valley to investigate, understand the production and operation of Shenzhen Cell Valley, and provide help for the development of enterprises and biomedical industry. Shi Yuanyuan, chairman and general manager of Shenzhen Cell Valley, and Wang Jianxun, chief scientist of Shenzhen Cell Valley, warmly received and carried out discussions and exchanges.


First of all, Deputy Director Yuan Shuai and his delegation, accompanied by Chairman Shi Yuanyuan and Director Luan Zhishi of the General Office, visited the Smart exhibition Hall and had a preliminary understanding of the company's founder team, corporate development history, history and status quo of cell therapy, service platform construction and corporate vision. In the emerging industry of biomedicine, Shenzhen Cell Valley provides one-stop cell therapy services for hospitals and pharmaceutical companies with the initial intention of curing diseases and saving lives.

At the symposium, Chairman Shi Yuanyuan warmly welcomed the visit of the leaders of the District Science and Technology Innovation Bureau, and reported to the leaders the rapid development of Shenzhen Cell Valley, the advantages of the company's core technology - retroviral vector GMP industrial production, and the unique value of providing standardized and professional services for the upstream and downstream links of the cell and gene therapy industry. Deputy Director Yuan Shuai said that recently, in order to accelerate the construction of the gradient cultivation system of biomedical enterprises and play the leading role of Pingshan national biomedical industry base, the district government has introduced many targeted and highly operational special support policies for the biomedical industry, and the District Science and Technology Innovation Bureau will continue to play the policy advantages of the special zone, around the biomedical industry chain, and continue to layout the research and development innovation chain. In the scientific and technological system, we will attract talents through innovation and development, and constantly improve the service platform for the development of cell and gene therapy industry through policy support.

Chairman Shi Yuanyuan expressed his sincere thanks to Vice Director Yuan Shuai for the attention and support of Shenzhen Cell Valley and the field of cell and gene therapy. Shenzhen Cell Valley will make full use of advanced technology and talent reserves, aiming at solving the pain points in the field of cell gene therapy in China, helping to build and integrate the construction of cell drug industry chain, truly benefiting tumor patients, protecting human life and health, and making greater contributions to promoting the development of biomedicine in Shenzhen.